At the CVCT 2024 Global Forum, PHRI researchers delivered a range of presentations on cardiovascular research design and inclusivity, and the latest insights from stroke prevention research.
Senior Scientist Harriette Van Spall addressed the lack of diversity in trial leadership and the challenges faced by women leaders in clinical trials. She highlighted opportunities to overcome these barriers for inclusive research. In another presentation, Van Spall also outlined three approaches for conducting Effectiveness-Implementation Hybrid studies, with the PACT-HF and VICTORY-HF studies as examples.
@hvanspall eloquently explains implementation trials and identifies 3 types of the Effectiveness-Implementation Hybrid Trials. Examples were provided for each type.#CVCT2024 @CVCTForum pic.twitter.com/uB5ceITyfL
— Dr Rani Khatib FESC (@DrRaniKhatib) December 10, 2024
Additionally, she presented and participated in a panel discussion on strategies for designing phase 3 trials to ensure successful implementation and promoting inclusivity in cardiology clinical trials.
@hvanspall “How to build implementation research plans into Phase 3 Trials” @CVCTForum #CVCT2024 #CVCT24 pic.twitter.com/IxaL9L9dKG
— Dr.Rajiv Sankaranarayanan (@DrRajivsankar) December 10, 2024
Scientist Sanjit Jolly chaired a session on “The Future of Post-MI Drug Therapy Trials” during which he presented main findings and meta- analysis of the CLEAR-SYNERGY study.
In a session titled ‘Thrombosis Trials: What is happening with factor XI inhibitors?’ Scientist Mike Sharma presented on Oral Factor XIa Inhibitor Trials in Secondary Stroke Prevention” highlighting the OCEANIC-STROKE study.
Photo courtesy of CVCT Forum.
